Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vagina antisepsis pharmaceutical gel

A gel, vaginal technology, applied in antibacterial, antifungal, drug combination and other directions, can solve the problems of destroying the vaginal acid-base balance environment, unfavorable for patients with gynecological diseases, slow onset time, etc., to protect and repair the vagina Mucous membranes, preventing recurrent inflammation, increasing elasticity and sensitivity

Inactive Publication Date: 2017-03-29
甘起伍
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, while various lotions kill germs, they also kill vaginal bacilli that are beneficial to the body and destroy the acid-base balance environment in the vagina. Long-term use will greatly reduce immunity and increase the chance of re-infection with germs
There are also some oral medications for gynecological inflammation, but these oral medications enter the vagina through blood circulation to kill bacteria, and the onset time is relatively slow, and they need to be taken for a long time to be effective, and they have serious side effects
Therefore, topical medication is preferred for the treatment of gynecological cervical and vaginal diseases. However, the existing external vaginal medications have poor bactericidal effect, high irritation, easy to repeat, and skin allergies, and the therapeutic effect is not ideal.
[0005] The above situation shows that the existing drugs for the treatment of gynecological vaginal diseases have large side effects and poor curative effect, resulting in strong dependence of patients, which is not conducive to the physical and psychological trauma repair of the majority of gynecological disease patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] In order to make the technical means, creative features, goals and effects achieved by the present invention easy to understand, the present invention will be further described below in conjunction with specific embodiments.

[0018] The invention provides a technical solution: a gel for vaginal antibacterial medicine, which is composed of the following raw materials in parts by weight: 6-8 parts by weight of flavescens, 10-12 parts by weight of safflower, 7-13 parts by weight of dried blood, 4-6 parts by weight of chitosan, 2-4 parts by weight of polycarbophil, 2-4 parts by weight of tea tree essential oil, 3-6 parts by weight of triethanolamine, 2-4 parts by weight of emulsifier, 6-9 parts by weight of carbomer Parts by weight, Fructus Cnidii 8-10 parts by weight, methyl p-hydroxybenzoate 1-2 parts by weight.

[0019] The emulsifier is formed by mixing one or more of sodium lauryl sulfate, Tween, span, stearic acid and triethanolamine.

[0020] Tea tree essential oil...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a vagina antisepsis pharmaceutical gel which is prepared from the raw materials of, by weight, 6-8 parts of raix sophorae flavescentis, 10-12 parts of safflower carthamus, 7-13 parts of dragon's blood, 4-6 parts of modified chitosan, 2-4 parts of polycarbophil, 2-4 parts of tea tree essential oil, 3-6 parts of triethanolamine, 2-4 parts of emulgators, 6-9 parts of carbomer, 8-10 parts of selinum japenious seeds and 1-2 parts of methyl parahydroxybenzoats. Compared with the prior art, the vagina antisepsis pharmaceutical gel has the beneficial effects that inflammation diminishing and itching relieving can be fast achieved, peculiar smell can be removed, cross infection of various pathogens in sex life is interrupted, yin nourishing is achieved, microfloras are regulated, the acid-alkali level is balanced, the vagina mucosa is protected and repaired, the moving plicae are constringed and tightened, the elasticity and the sensitiveness are improved, foundational nursing is achieved in true sense, the reproductive function is improved, recurrent attacks of inflammation are prevented, recovery occurs without treatment, and meanwhile, the physiological function can be improved.

Description

technical field [0001] The invention is a gel for vaginal antibacterial medicine, which belongs to the field of drug synthesis. Background technique [0002] With the development of society and the constant changes in people's lifestyles and behaviors, the prevalence of various gynecological diseases, such as reproductive tract infections, menstrual disorders and breast diseases, is gradually increasing. Gynecological infectious diseases are a common and frequently-occurring disease, especially mycotic vaginitis, cervical erosion and senile vaginitis, which have a high incidence rate, and various chronic cervical diseases have plagued the majority of female friends all year round. [0003] For example, simple vulvovaginal candidiasis (SVVC) is a gynecological reproductive tract infection caused by the excessive reproduction of Candida in the vagina. The most common infection is Candida albicans, with a prevalence of about 5% of married women of childbearing age. SVVC tends...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/896A61K9/06A61K47/32A61P15/02A61P31/04A61P31/10A61K31/722
CPCA61K36/489A61K9/0034A61K9/06A61K31/722A61K36/234A61K36/286A61K36/61A61K36/889A61K36/896A61K47/32A61K2300/00
Inventor 甘起伍
Owner 甘起伍
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products